Thymosin-Beta-4 (TB-500 oral) 30 caps

Thymosin Beta-4 Fragment + ARG BPC-157 is two-component research reagent in the form of HPMC capsules for oral administration, containing active fragment of Thymosin Beta-4 (LKKTETQ, commercially known as TB-500) and arginine salt BPC-157 (ARG BPC-157). Each active ingredient has its own regulatory status – and none of them make this reagent a drug. Neither peptide is registered as medicinal products in any jurisdiction.

BPC-157 has been on the WADA Prohibited List under Section S0 (Unapproved Substances) since 2022 and Thymosin Beta-4/TB-500 has been on the Prohibited List under Section S2 (Peptide Hormones, Growth Factors and Mimetics) since 2011 — both prohibited at all times, both in and out of competition. The oral form of peptides is additionally associated with low gastrointestinal bioavailability – details below.

Communication suggesting human use for accelerated recovery, tendon healing, muscle repair, or any health effect is inconsistent with the Research Use Only framework and is unacceptable.

Connective tissue repair is one of the most difficult problems in regenerative biology. Chronic tendon injury, slowly healing wound, recurrent muscle tear – in each of these cases, the pace and quality of repair depend on the coordinated work of many processes: migration of repair cells to the site of damage, construction of new vessels supplying oxygen and substrates, synthesis of collagen that rebuilds the matrix and silencing of inflammation.

No single pathway is responsible for the entire process – which is why researchers are interested in combinations of molecules operating at different, complementary levels of repair. In the research catalogue, this mechanism is represented by the entire category peptides for regeneration, in which two-component blends constitute a separate segment. Blend Thymosin Beta-4 Fragment + ARG BPC-157 is such a research pair – a combination of two peptides that are attributed to different mechanisms in the literature on tissue regeneration.

Active fragment of Thymosin Beta-4 (LKKTETQ) operates at the level of the cytoskeleton – it binds monomeric G-actin and modulates the dynamics of its polymerization, i.e. the apparatus that determines the ability of cells to move. BPC-157 — stable gastric pentadecapeptide — acts primarily through the angiogenesis axis (VEGF/VEGFR2), the adhesion complex (FAK-paxillin) and local cytoprotection.

Two different entry points, two different cascades, one common area of ​​interest: tissue repair. This is the rationale for which the BPC-157 + TB-500 pair is one of the most frequently used “regeneration stacks” in experimental protocols. Single-component lines remain available in parallel: BPC-157 PEN and TB-500 10mg as reference points for comparative studies on each peptide separately.

To understand why you need to combine two peptides that act on tissue repair, you need to see that the repair of damaged tissue is not a single event, but a sequence of overlapping phases – inflammatory, proliferative and remodeling. Each of these phases involves a different set of cellular processes, and research peptides differ in which of these processes they affect most strongly. BPC-157 and the Tβ4 fragment are a classic example of a pair whose combination makes sense precisely because their mechanisms do not overlap, but complement each other.

BPC-157 – angiogenesis and repair by VEGF/FAK. BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from the protein sequence of gastric juice. Its effects have been described in preclinical models angiogenesis via the VEGFR2 pathway – i.e. the construction of new blood vessels – and on FAK-paxillin complex, central to endothelial cell adhesion and migration.

Additionally, the literature indicates modulation of the nitric oxide pathway (NO/eNOS) and anti-inflammatory effects related to the influence on the NF-κB pathway. Accelerated new vessel formation and improved tendon repair parameters have been reported in tendon healing models (Chang et al. 2011) – a trend that has made BPC-157 one of the most frequently cited peptides in connective tissue research.

TB-500 (Tβ4 fragment) – cell migration through the cytoskeleton. The active fragment of Thymosin Beta-4, the heptapeptide LKKTETQ, starts at a different level – from cytoskeleton. Parent Tβ4 binds monomeric G-actin and regulates the pool of monomers available for the construction of F-actin filaments, and thus the cell’s ability to reorganize the skeleton and migration.

Migrating fibroblasts, keratinocytes and endothelial cells are the foundation of every reparation – without the movement of repair cells, the wound does not close. The LKKTETQ fragment retains the actin-binding motif responsible for this mechanism. Why together. This is the essence of the “regeneration stack”. BPC-157 provides new vessels and a cytoprotective signal (VEGF/FAK/NO axis), and the Tβ4 fragment supports the movement of repair cells to the site of damage (cytoskeletal axis).

Two complementary arms of reparation in one reagent – this is a model that allows studying both axes in parallel, in one controlled experimental system, in research protocols on tissue repair. This mechanism is also the background for the entire group peptides for injuries, in which the pair of BPC-157 and the Tβ4 fragment is among the best characterized combinations.

A constant proportion of both peptides in the capsule simplifies protocols in which both molecules are to be present together. The same caveat comes back and is not a formality: data from the literature describe observations in cellular and animal models and in small clinical programs of full Tβ4. The RUO reagent is not a therapeutic form, and the oral form of the peptides further complicates extrapolation – gastrointestinal bioavailability is low. The role of this tool ends at the laboratory bench.

Blend it a combination of two distinct peptides in an HPMC capsule, in the proportion indicated in the batch COA. Both peptides are available on the RUO market in variants that are easy to confuse – therefore, below is the description of each of them separately, along with the distinction between the structural variants.

Ingredient 1 – Thymosin Beta-4 Fragment (TB-500, LKKTETQ)

It is most often sold under the trade name “TB-500”. active fragment of Thymosin Beta-4 — seven-amino acid heptapeptide LKKTETQ (Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln), the so-called “actin-binding motif”. This is a short section derived from the full-molecular protein Thymosin Beta-4 (Tβ4), which consists of 43 amino acids. The fragment retains the motif responsible for the interaction with monomeric G-actin, but does not reproduce the full repertoire of biological activity of the entire protein – full Tβ4 carries additional domains involved in angiogenesis, modulation of inflammation and reepithelialization, which the heptapeptide itself does not fully replicate.

Ingredient 2 – ARG BPC-157 (arginine salt BPC-157)

BPC-157 (Body Protection Compound 157) is synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV – a stable gastric peptide derived from the protein of gastric juice. RUO BPC-157 is available in the form of: different salts, which must not be confused because they affect the stability and solubility of the molecule:

• ARG BPC-157 (arginine salt) – BPC-157 with arginine as a counter-ion. Arginine as a counterion increases the stability and solubility of the peptide compared to the free form. This is the variant included in this blend.
• BPC-157 acetate (acetate) — BPC-157 with acetate as counterion; the most common form of salt in the peptide reagent market.

The most important distinction: salt does not change the peptide sequence — in both cases the amino acid chain is the same GEPPPGKPADDAGLV. Only the counterion is different, which translates into the mass of the salt (and not the mass of the peptide itself) and the physicochemical properties (stability, solubility, hygroscopicity). The identity of the peptide is determined by the sequence and mass confirmed by mass spectrometry in COA – with the mass measured for the salt differing from the mass of the free peptide by the contribution of the counterion.

The operation of the blend is based on two separate, complementary mechanisms of tissue reparation — different for each peptide. This is what distinguishes this reagent from a single regenerative peptide: it is not about one stronger stimulus, but about two different entry points in the repair cascade.

BPC-157 axis – angiogenesis, adhesion foci, cytoprotection. BPC-157 affects primarily: building new blood vessels. Its effects on the pathway have been described in preclinical models VEGF/VEGFR2 — vascular endothelial growth factor receptor, central switch of angiogenesis. In parallel, the peptide affects FAK-paxillin complex (adhesion foci kinase), which determines the adhesion and migration of endothelial cells – i.e. the ability of these cells to organize into vascular structures.

The third thread is nitric oxide pathway (NO/eNOS), related to vasodilation and blood flow, and NF-κB modulation, combining the action of BPC-157 with silencing inflammation. In a working analogy: BPC-157 builds the tissue delivery infrastructure – the vessels through which oxygen and substrates reach the site of repair.

TB-500 axis (Tβ4 fragment) – cytoskeleton and migration. The LKKTETQ fragment works through a completely different apparatus – through actin cytoskeleton. Parental Tβ4 binds monomeric G-actin and regulates the pool of free monomers available for the construction of F-actin filaments. The actin cytoskeleton is responsible for the shape of the cell and its ability to move, so the modulation of this pool translates into migration of repair cells. In an analogy: if BPC-157 builds roads, the Tβ4 fragment sets in motion vehicles – cells that use these roads to reach the damage and rebuild the tissue.

Complementarity, not redundancy. This is the essence of the combination of both peptides. Because they work through different mechanisms — BPC-157 by angiogenesis and cytoprotection (VEGF/FAK/NO), Tβ4 fragment by cytoskeletal dynamics and migration – their activity ranges do not overlap, but complement each other at different stages of reparation. New vessels (BPC-157) without migrating repair cells (Tβ4) will not regenerate tissue; migrating cells without a supply of oxygen and substrates will also get stuck.

The “regeneration stack” model in research protocols is based precisely on this complementarity – two repair arms studied together, in one system. This is a mechanistic summary, not a statement of aggregated clinical effect.

Working with this blend requires conceptual discipline on three levels. Each of them can lead to misinterpretation of results if omitted.

First – TB-500 fragment vs full Thymosin Beta-4. “TB-500” is a trade name, not the name of one defined molecule. RUO is most often marketed under this name active fragment of LKKTETQ (7 amino acids, ~889 g/mol) – actin binding motif itself. Full-molecule Thymosin Beta-4 is a protein with 43 amino acids (~4963 g/mol), carrying additional activity domains.

These are two different molecules with different masses, different pharmacokinetic profiles and partly different biological activity repertoire. Most of the literature cited below describes the whole protein – when interpreting each observation, the question must be asked whether we are talking about full Tβ4 or a fragment.

Secondly – ARG BPC-157 (arginine salt) vs BPC-157 acetate. “BPC-157” is a peptide sequence (GEPPPGKPADDAGLV), but is marketed as different salts. ARG BPC-157 is an arginine salt – BPC-157 with arginine as a counterion, which increases stability and solubility. BPC-157 acetate (acetate) is a variant with acetate as a counterion. The peptide sequence is identical in both cases – only the counterion differs.

Consequence: the mass measured by spectrometry for the salt differs from the mass of the free peptide by the contribution of the counterion, and the physicochemical properties (stability, solubility, hygroscopicity) depend on the type of salt. Salt doesn’t change that What makes a peptide, but it affects How behaves in storage and in solution.

Third – oral bioavailability of peptides. This is a distinction specific to this form. Peptides administered orally encounter proteolytic enzymes in the gastrointestinal tract (pepsin, trypsin, intestinal peptidases), which break down the amino acid chain before the molecule enters the circulation. This is why the oral bioavailability of most peptides is low — a significant part of the dose is digested.

BPC-157 is a partial exception here: its term “stable gastric pentadecapeptide” refers to above-average proteolytic stability in the gastric environment, described in the preclinical literature – this is a feature that makes it an interesting subject of research on oral administration. However, for the Thymosin Beta-4 fragment, oral bioavailability is available subject to verification — there are no grounds to assume high systemic availability of heptapeptide administered orally.

The capsule form of this blend is therefore honestly positioned as research reagent, where the bioavailability of each ingredient is a separate experimental question rather than a predefined property.

Blend Thymosin Beta-4 Fragment + ARG BPC-157 as a two-component RUO reagent is used where the subject of the study is interaction of two complementary tissue reparation mechanisms — angiogenesis and cytoprotection (BPC-157) with cytoskeletal dynamics and cell migration (Tβ4 fragment). A constant proportion of both peptides in the capsule simplifies protocols in which both molecules are to be present together. Specific research directions include:

• Pharmacology of complementary reparation mechanisms — comparison of the effect on tissue reparation when exposed separately to BPC-157, separately to the Tβ4 fragment and to both peptides simultaneously; characterization of whether effects are additive or potentiating in tendon, muscle, and skin healing models
• Angiogenesis (BPC-157 axis) — tube formation assays, vascularization models, measurements of VEGF/VEGFR2 expression and FAK-paxillin complex activity in endothelial cell cultures
• Cell migration and cytoskeleton dynamics (Tβ4 axis) — migration tests (scratch assay, transwell), imaging of F-actin dynamics, measurements of the effect on G-actin sequestration in cultures of fibroblasts, keratinocytes and endothelial cells
• Models of connective tissue reparation — animal models of tendon, muscle and skin damage; endpoints: wound closure rate, collagen I/III density, scar histology, biomechanical parameters of the repaired tissue
• Studies on the oral bioavailability of peptides — comparison of proteolytic stability and systemic availability of BPC-157 (stable gastric pentadecapeptide) and Tβ4 fragment after oral administration in animal models; characterization of the influence of the salt form (arginine vs. acetate) on stability in the gastrointestinal tract environment
• The influence of salt form on physicochemical properties — comparison of stability, solubility and hygroscopicity of BPC-157 arginine salt and BPC-157 acetate under storage conditions and in solution

REGULATORY STATUS

Both peptides are on the WADA Prohibited List in different sections. BPC-157 is listed in section S0 (unapproved substances) — a category covering pharmacological substances with no current approval from any regulatory authority for human therapeutic use; BPC-157 added to the list in 2022. Thymosin Beta-4 / TB-500 is located in section S2 (peptide hormones, growth factors, related substances and mimetics) since 2011.

Both substances are there prohibited permanently — both in and out of competition. There is an absolute ban for registered athletes (ADAMS). Neither BPC-157 nor Thymosin Beta-4 (whole protein or fragment) is approved as a medicinal product in the EU, US or anywhere in the world – clinical programs for full Tβ4 (RegeneRx) have been partially abandoned and have not resulted in authorization. Registered athletes must check the current list of prohibited substances before making any decision regarding use.

Thymosin Beta-4 Fragment + ARG BPC-157 is two-component RUO research reagent in the form of HPMC capsules for oral administration, combining two peptides with complementary tissue reparation mechanisms: active fragment of Thymosin Beta-4 (LKKTETQ), acting at the level of the cytoskeleton and cell migration by binding G-actin, and arginine salt BPC-157 (ARG BPC-157), acting through angiogenesis (VEGF/VEGFR2), the FAK-paxillin complex, the NO/eNOS pathway and NF-κB modulation.

The rationality of this “regenerative stack” lies in complementarity: BPC-157 builds vascular infrastructure and a cytoprotective signal, and the Tβ4 fragment supports the movement of repair cells – two different arms of repair, studied together. Working with the reagent requires differentiation at three levels: LKKTETQ fragment vs. full Tβ4 (~889 vs. ~4963 g/mol), BPC-157 arginine salt vs. acetate (same sequence, different counterion), and awareness that oral bioavailability of peptides is low — BPC-157 is distinguished by proteolytic stability, but the availability of the Tβ4 fragment remains subject to verification.

The sequence and mass from the batch COA are the only binding identity signals for both peptides. HPLC purity ≥98% for both components, MS Q-TOF, COA for each batch with confirmation of proportion and salt variant. Regulatory Status – Research Use Only; lack of registration as a medicine; WADA: BPC-157 section S0, TB-500 section S2, both prohibited permanently.

1. Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. PubMed
2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. PubMed
3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. PubMed
4. Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. PubMed
5. Crockford D, Turjman N, Allan C, Angel J (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. PubMed